Gloria Jung

Senior Practice Development Manager

jung-gloria
  • JD, Vanderbilt University Law School, 2005
  • BS (Chemistry), highest honors, Georgia Institute of Technology, 2002

Qualifications

  • New York, 2006
  • U.S. Patent and Trademark Office, 2005

Court Admissions

  • U.S. District Court for the Eastern District of New York, 2006
  • U.S. District Court for the Southern District of New York, 2006
  • American Bar Association
  • New York Bar Association

Gloria Jung

Senior Practice Development Manager

Gloria is the senior practice development manager for the intellectual property litigation practice group. She supports the practice group leader in the management of the practice, particularly in the areas of strategic business planning, business development, marketing, knowledge management, lateral attorney on-boarding and integration, financial analysis and logistical support. Gloria also oversees practice development professionals supporting the Tokyo and Seoul offices.

Experience

  • Prior to joining Ropes & Gray, Gloria was a senior associate at Shearman & Sterling in New York where she practiced for over six years in the intellectual property transactions and mergers & acquisitions groups handling all aspects of transactions involving the sale, purchase or licensing of intellectual property assets. Gloria also counseled clients on intellectual property and data privacy issues in all types of corporate and financial transactions including outsourcing arrangements, patent monetization, securing intellectual property in debt transactions and acting as underwriter’s intellectual property counsel in various initial public offerings. Gloria has worked with clients in a variety of industries including software and technology vendors, life sciences and biotechnology corporations, multimedia corporations and financial institutions. 
  • Prior to Shearman & Sterling, Gloria was an intellectual property litigation associate at Fitzpatrick, Cella, Harper & Scinto. Gloria’s practice at Fitzpatrick focused on patent litigation under the Hatch-Waxman Act in the pharmaceutical sector.